- Celonic appointed Alexandre Pasini as Chief Operating Officer
- Alexandre brings a wealth of experience from a 25-year career, which includes leading operational roles at SaniSure Group Ltd and Lonza Group Ltd
- Alexandre succeeds Vikalp Mohan, who remains head of the commercial department as the new Chief Business Officer (CBO)
BASEL, Switzerland, October 28, 2021 / B3C newswire / -- Celonic Group, a Swiss-German contract development and manufacturing organization (CDMO), has appointed Alexandre Pasini as the new Chief Operating Officer of Celonic Group. The appointment is effective from 15 October 2021. He will succeed Vikalp Mohan, who will continue to lead the commercial department as the new Chief Business Officer.
“I am happy to welcome Alex to our leadership team as the new Chief Operating Officer. He is an accomplished and respected leader with an impressive track record in the biopharma sector. His appointment strengthens Celonic’s continuing focus on Operational Excellence to deliver outstanding services beyond biomanufacturing and an unmatched customer experience.” said Dr. Konstantin Matentzoglu, Chief Executive Officer of Celonic.
Alexandre joins Celonic Group after having served as Chief Operating Officer at SaniSure Group Ltd, a leading supplier of single-use technologies to the life sciences industry. Before joining SaniSure, he held, for more than ten years, several leading operational roles at Lonza Group Ltd, ranging from Site Director to Head of Global Bioscience Operations.
Alexandre holds a post-graduate degree in Econometrics & Mathematical Economics and a Master of Science Degree in Economics at the University of Geneva (CH), and is a Certified Financial Analyst (CFA). He earned both Black Belt and Green Belt Certifications in Operational Excellence.
Alexandre Pasini says: “I am extremely excited to join the Celonic team as I strongly believe in the company’s mission and chances of success. I am passionate about helping save patients’ lives, and am convinced Celonic will continue to do so by focusing on continuous manufacturing improvement to best serve our customers”.
Celonic, a global CDMO (contract development & manufacturing organization) for innovative biopharmaceuticals, including cell and gene therapy products, is part of the private and independent family-owned company J.RETTENMAIER & Söhne (JRS-Group), with currently two production sites – in Basel, Switzerland (headquarters) and Heidelberg, Germany. Celonic provides comprehensive development and manufacturing services for biotherapeutics including cell line development, USP and DSP development, GMP and non-GMP manufacturing of biopharmaceutical drug substances and drug products, along with cell expression platforms and diagnostics. With a new state-of-the-art GMP manufacturing facility for gene vectors and cell therapy, Celonic is expanding its existing ATMP development and GMP manufacturing capacity in the upcoming Life Science Park Rheintal in Stein, Switzerland.
Digital Marketing Lead
+41 61 56 49 150
Published by B3C newswire